All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression kidney transplant recipients obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline solid cancer solid organ transplant recipients subjects at risk
vaccines in COVID-19 prophylaxis (children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed Covid-19, from 1st dosedetailed results C4591001 (Adolescents 12-25), 2021 0.08 [0.02; 0.34]
0.08 [0.02 ; 0.34 ] C4591001 (Adolescents 12-25), 2021 1 0% 2,260 NA not evaluable confirmed COVID (any severity)detailed results kidCOVE (part 2), 2022 0.26 [0.16; 0.42]
PREVENT-19 adolescents, 0 0.18 [0.05; 0.68]
teenCOVE (P203) (Adolescents 12-17Y), 2021 0.07 [0.01; 0.46]
Walter E.B. (Children <12 Years of Age), 2021 0.09 [0.03; 0.32]
0.19 [0.11 ; 0.32 ] kidCOVE (part 2), 2022, PREVENT-19 adolescents, 0, teenCOVE (P203) (Adolescents 12-17Y), 2021, Walter E.B. (Children <12 Years of Age), 2021 4 19% 9,424 NA not evaluable symptomatic Covid-19detailed results C4591001 (Adolescents 12-25), 2021 0.03 [0.00; 0.50]
kidCOVE (part 2), 2022 0.12 [0.04; 0.32]
0.10 [0.04 ; 0.26 ] C4591001 (Adolescents 12-25), 2021, kidCOVE (part 2), 2022 2 0% 5,985 NA not evaluable asymptomatic COVID casedetailed results kidCOVE (part 2), 2022 0.38 [0.20; 0.69]
0.38 [0.20 ; 0.69 ] kidCOVE (part 2), 2022 1 0% 4,002 NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results C4591001 (Adolescents 12-25), 2021 0.25 [0.05; 1.13]
0.25 [0.05 ; 1.13 ] C4591001 (Adolescents 12-25), 2021 1 0% 2,239 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-30 20:19 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 330
- treatments: 551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803
- roots T: 290
